NeuroPhage Extends Series B to $21.4M
CAMBRIDGE, Mass., March 8, 2012 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. (NeuroPhage), a privately held biotechnology company focused on a novel approach for disaggregating misfolded proteins for the treatment and prevention of neurodegenerative diseases, announced today that it has secured $9.0 million in Series B-1. Dr. Michael Grundman , an Alzheimer's disease clinical expert, President and CEO of the consulting firm Global R& D Partners, LLC, has joined the NeuroPhage team to lead the clinical development of NPT002. The round was completed by existing investors, including Merieux Developpement, Shire, and private investors. The Series B-1 financing brings the total amount of equity capital raised by NeuroPhage since its inception in 2006 to $28.6 million. The terms of the financing were not disclosed.
Dr. Richard Fisher , NeuroPhage's CSO said: "The continued support of all of our investors enables us to fully exploit our recent breakthrough around the mechanism of action of NPT002."
NeuroPhage is a biotechnology company focusing on a unique approach for treating diseases involving protein aggregation. NeuroPhage was founded in 2007 by a Cambridge-based team along with Professor Beka Solomon , Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University.
SOURCE NeuroPhage Pharmaceuticals, Inc.
More by this Source
NeuroPhage, Inc. Raises $6.4 Million In Additional Financing
May 06, 2013, 07:30 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.